Adrenomedullin vs Thymosin Beta-4
A powerful vasodilatory peptide that relaxes blood vessels and helps your body maintain healthy fluid balance and blood pressure.
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Adrenomedullin
10–10 ng/kg/min
Thymosin Beta-4
2–5 mg
Frequency
Adrenomedullin
Once daily
Thymosin Beta-4
Twice weekly
Administration
Adrenomedullin
Intravenous infusion
Thymosin Beta-4
Subcutaneous injection
Cycle length
Adrenomedullin
Ongoing/indefinite
Thymosin Beta-4
8-12 weeks
Onset speed
Adrenomedullin
Moderate (1-2 weeks)
Thymosin Beta-4
Moderate (1-2 weeks)
Evidence level
Adrenomedullin
Moderate human trials (Phase 1-2)
Thymosin Beta-4
Moderate human trials (Phase 1-2)
Benefit ratings
Cardiovascular Support
Tissue Protection
Immune Function
Wound Healing
Inflammation Reduction
Tissue Regeneration
Compound specifications
Adrenomedullin
Molecular formula
C264H406N80O77S3
Molecular weight
6029 Da (Daltons)
Half-life
Approximately 20-30 minutes in plasma (rapid metabolism)
Bioavailability
Parenteral administration only; peptide undergoes proteolytic cleavage in circulation
CAS number
148498-78-6
Thymosin Beta-4
Molecular formula
C212H350N56O78S
Molecular weight
4963
Half-life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS number
77591-33-4
Dosing compared
Adrenomedullin
Intravenous
5 ng/kg/min
Continuous infusion, 8 hours per day · 14 days (trial protocol)
Adrenomedullin is given as a slow drip into a vein in clinical trials, not by self-injection. This low dose was the bottom step tested for steroid-resistant ulcerative colitis. [4]
10 ng/kg/min
Continuous infusion, 8 hours per day · 14 days (trial protocol)
Middle dose tested in the ulcerative colitis trial. [4]
15 ng/kg/min
Continuous infusion, 8 hours per day · 14 days (trial protocol)
This higher dose was the only one that significantly improved disease scores in the trial. The same 15 ng/kg/min rate was also tested safely in healthy volunteers. [4][5]
Thymosin Beta-4
Subcutaneous injection
2-5 mg (community injectable practice for 'TB-500')
Once or twice weekly · 4-6 week loading phase, then weekly maintenance
Documented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.
Topical ophthalmic (eye drops)
0.1% (1 mg/mL) RGN-259 solution, 1 drop
Several times daily (e.g. up to 5x/day) · 4 weeks
0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].
Intravenous injection
450-1200 mg
IV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeks
Doses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].
Best suited for
Adrenomedullin
Cardiovascular health optimization
Adrenomedullin is particularly well-suited for individuals focused on cardiovascular health optimization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Maintaining healthy blood pressure
Adrenomedullin is particularly well-suited for individuals focused on maintaining healthy blood pressure. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Recovery from illness or sepsis
Adrenomedullin is particularly well-suited for individuals focused on recovery from illness or sepsis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tissue protection and oxygen delivery
Adrenomedullin is particularly well-suited for individuals focused on tissue protection and oxygen delivery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions
Side effects
Adrenomedullin
Common
- Mild discomfort at treatment site
- Excessive blood pressure lowering (hypotension)
- Headaches (from pressure changes)
- Flushing and mild facial redness
- Dizziness or lightheadedness
- Mild electrolyte shifts
- Localized injection site reactions
- Increased urination (natriuretic effect)
Serious
- Severe allergic reaction
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Safety & evidence
Adrenomedullin
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Adrenomedullin safety in humans is poorly characterized, with clinical data limited to observational studies and small uncontrolled trials in cardiovascular patients. Animal studies demonstrate potent vasodilatory effects that could lower blood pressure dangerously, particularly in patients on antihypertensive medications. No human pharmacokinetic studies have established safe doses, and potential for hypotension, electrolyte disturbances, and off-target vasodilation effects exists. The peptide crosses the blood-brain barrier and affects central nervous system function in animal models, raising concerns about neurological effects at higher doses.
Contraindications
- Severe hypotension or shock states
- Concurrent use with certain vasopressor medications
- Pregnancy and breastfeeding
- Severe kidney or liver dysfunction
Thymosin Beta-4
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- Active systemic infections
- Severe immunosuppression
- Hypersensitivity to thymosin or any component
- Pregnancy (insufficient safety data)
Which is right for you?
Choose Adrenomedullin if...
- Cardiovascular health optimization
- Maintaining healthy blood pressure
- Recovery from illness or sepsis
- Tissue protection and oxygen delivery
Choose Thymosin Beta-4 if...
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation